Ocular Genomics
243 Charles Street Boston, MA 02114 Contact us
Diagnostic Testing
Support our research
Explore our labs
Ocular Genomics MENU
Ocular Genomics
  • Meet the Team
  • Services
    • Biobank Core Services
    • Bioinformatics and Statistics Core
    • Functional Genomics (Zebrafish) Core
    • Gene Transfer Vector
      • Rates
      • Order Information
      • Contact Us
    • Genetic Diagnostic Testing Service
      • Pricing
    • Genomics Core Services
      • Additional Genomics Services
      • Sanger Sequencing
      • Array Analysis
      • Next-Generation Sequencing (NGS)
  • Labs
    • Biobank Core
    • Bujakowska Lab
      • Lab Members
      • Publications
    • Comander Lab
      • Lab Members
      • Publications
    • Engle Lab
    • Functional Genomics Core (Zebrafish Facility)
      • Lab Members
    • Genetic Counseling Team
      • Team Members
    • Genomics Core Lab
      • Lab Members
    • Liu Lab
      • Lab Members
      • Publications
      • Projects
    • MEEI Bioinformatics Center (MBC)
      • Lab Members
    • Pierce Lab
      • Lab Members
      • Publications
      • Projects
    • Segrè Lab
      • Selected Publications
    • Vandenberghe Lab
      • Lab Members
    • Wiggs Lab
      • Lab Members
    • Mary Whitman
      • Lab Members
    • iPS Research Lab
      • Lab Members
      • Grant support
      • Publications
  • News & Publications
    • RETINAL Transcriptome
  • Affiliates
  • Careers
  • Home
  • Labs
  • Liu Lab
  • Projects
  • Genome editing for USH2A associated IRD

LABS

  • Biobank Core
  • Bujakowska Lab
    • Lab Members
    • Publications
  • Comander Lab
    • Lab Members
    • Publications
  • Engle Lab
    • Publications
  • Functional Genomics Core (Zebrafish Facility)
    • Lab Members
  • Genetic Counseling Team
    • Team Members
  • Genomics Core Lab
    • Lab Members
  • iPS Research Lab
    • Grant support
    • Lab Members
    • Publications
  • Liu Lab
    • Lab Members
    • Publications
    • Projects
      • Retinitis Pigmentosa 1
      • Genome editing for dominant IRDs
      • Genome editing for USH2A associated IRD
  • MEEI Bioinformatics Center (MBC)
    • Lab Members
  • Pierce Lab
    • Lab Members
    • Publications
    • Projects
      • Retinal Degeneration Disease Gene Discovery
      • NMNAT1 Leber Congenital Amaurosis (LCA)
      • Novel Photoreceptor Sensory Cilia Proteins
      • RNA Splicing Factor Retinitis Pigmentosa/Transcriptome Analyses
      • Pericentral Retinitis Pigmentosa
      • High-throughput Functional Studies of Sequence Variants
  • Segrè Lab
    • Selected Publications
    • Lab Members
  • Vandenberghe Lab
    • Lab Members
  • Whitman Lab
    • Lab Members
  • Wiggs Lab
    • Lab Members

Mutations in the gene USH2A are the prime cause of usher syndrome in humans and results in malfunctioning of USH2A protein, impaired vision and hearing loss. In United States, approximately 15%–30% of USH2A cases are due to these mutations. Utilizing CRISPR-Cas9, Homology Independent Targeted Integration (HITI) genomic editing and gene replacement tools we are currently investigating the mechanisms by which specific mutations in genes such as USH2A and CRX lead to blinding disease. Our proposed research aims to develop a CRISPR/Cas genome editing based therapeutic approach for retinal degeneration due to mutations in the USH2A gene, which is currently an unmet clinical need for 0.5-1.8 million of people worldwide. Given the high degree of repetitive regions in usherin protein, we postulate that an usherin protein that lacks one or more of the repetitive domains, such as mutation prone exon 13 in human, may have ability to retain partial of complete gene function. If this is true, the abbreviated USH2A, lacking deleterious or mutation prone regions, will have the potential to serve as a therapeutic strategy for Usher syndrome type II by skipping the mutant exon in USH2A gene.